3. its vih sida
DESCRIPTION
vih sidaTRANSCRIPT
![Page 1: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/1.jpg)
ITS - VIH
J. Urquiza Z. M.C. F.C.
![Page 2: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/2.jpg)
![Page 3: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/3.jpg)
![Page 4: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/4.jpg)
CLINDAMICINAEFICACIAFarmacodinamia: Bacteriostático. 50 s. Antianaerobio. Farmacocinética: VO-IM-EV. Max: 45’-60’. F. 90%. M-Elimin: H. E. Comparativa: < Metronidazol bacteroides fragilis.
SEGURIDADRAM: Intolerancia digestiva, diarrea. Trombocitopenia. Flebitis. Colitis PM.Interacciones: Caolin. Cloramfenicol, macrólidos. Relajantes musculares CI: Hipersensibilidad. Insuficiencia hepática. (B).
C/B: Bajo/Alto
DOSIS: IM-EV: 300-600 mg c/6-8h. Dosis máxima: 4 gNiños: 15 - 20 mg/kg/día c/8h. Dosis máxima: 2 g
![Page 5: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/5.jpg)
INFECCIONES GONOCOCICAS
CERVIX, URETRA Y RECTO FARINGE
CONJUNTIVITIS
MENINGITIS YENDOCARDITIS
INFECCION DISEMINADA
![Page 6: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/6.jpg)
CEFTRIAXONAEFICACIAFarmacodinamia: Bactericida. PBPs. Mureína hidrolasas. Farmacocinética: IM-EV. Max: 0,5 h IM. Vd ↑. Elimin. R/Biliar E. Comparativa: Resistencia betalactamasas. Espectro amplio.
SEGURIDADRAM: Intolerancia digestiva. Hipoprotrombinemia. Flebitis. Leucopenia. Interacciones: Aminoglucósidos. Vancomicina. Anfotericina B. Furosemida. CI: Hipersensibilidad. Insuficiencia Renal Severa. (B).
C/B: Bajo/Alto
DOSIS: IM-EV: 1 – 2 g c/24 h. Dosis máxima: 2 gNiños: 50-75 mg/kg c/12-24 h. RN: c/12. Dosis máxima: 2 g
![Page 7: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/7.jpg)
INFECCIONES POR CHLAMYDIA
ADULTOS Y JOVENES GESTANTES
![Page 8: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/8.jpg)
SIFILIS PRIMARIA SECUNDARIA Y LATENTE
SIFILIS PRIMARIA Y SECUNDARIA
SIFILIS LATENTE
![Page 9: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/9.jpg)
SIFILIS TERCIARIA, NEUROSIFILIS Y GESTACIONAL
SIFILIS TERCIARIA
NEUROSIFILIS
SIFILIS GESTACIONAL
![Page 10: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/10.jpg)
![Page 11: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/11.jpg)
![Page 12: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/12.jpg)
VIH - SIDA
![Page 13: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/13.jpg)
ZIDOVUDINA
EFICACIAFarmacodinamia: Trifosforilación x cinasas: (-) competitiva timidinaFarmacocinética: I: 30’vo. Max: 1h IC:4 h. F: 75%↓met LCR: 0,6E. Comparativa: VIH 1 y 2. Combinación, < inhibidores proteasa. <ITINN.
SEGURIDADRAM: Intolerancia, cefalea, anemia, mialgias neuritis periférica. hepatotoxicoInteracciones: Fluconazol, valproato. Sulfonamidas, anfotericina BCI: Anemia Hb <7,5 g/dL (C).
C/B: Bajo/Alto
DOSIS: VO: 300 mg c/12h Niños: 100 – 180 mg/m2 Neonatos: 2 mg vo c/6h (De 12 h a 6 sem)
![Page 14: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/14.jpg)
LAMIVUDINA
EFICACIAFarmacodinamia: Trifosforilación x cinasas: (-) competitiva citosinaFarmacocinética: I: 30’. Max: 1-3h IC: 18 h. F: 82% ER↑ LCR: 0,1E. Comparativa: VIH 1-2. VHB. Combinación, < inhibidores proteasa. < ITINN.
SEGURIDADRAM: Cefalea, naúseas, pancreatitis.Interacciones: Zalcitabina. Cotrimoxazol.CI: Hipersensibilidad (C).
C/B: Bajo/Alto
DOSIS: VO: 150 mg c/12h Niños: 4 mg/kg vo c/12h
![Page 15: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/15.jpg)
EFAVIRENZ
EFICACIAFarmacodinamia: (-) alostérico p66 timidina. Resistencia rápida.Farmacocinética: I: 30’vo. Max: 5h t1/2:50h F:↑ alim. LCR: 0,01E. Comparativa: VIH 1.Combinación, < inhibidores proteasa. >ITIN
SEGURIDADRAM: Eritema. Mareo, insomnio, alucinaciones. Cefalea.Interacciones: CYP3A4: Anticonvulsivantes. Rifampicina. CI: Insuficiencia hepática severa. Psicosis. (X).
C/B: Bajo/Alto
DOSIS: VO: 600 mg c/24 h
Niños: 200 – 400 c/24 h
![Page 16: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/16.jpg)
LOPINAVIR
EFICACIAFarmacodinamia: Análogos peptídicos (-) proteasa (pro) gag-polFarmacocinética: I: 30’vo. Max: 3h D: 8 h. F:50% Lop:4 x Rit:1E. Comparativa: Combinación, >ITIN e ITINN.
SEGURIDADRAM: Intolerancia. Dislipidemia. Lipodistrofia.Interacciones: (-) CYP3A4: Midazolam. Ergotamina. Amiodarona. Rifampicina.CI: Hipersensibilidad (B).
C/B: Bajo/Alto
DOSIS: VO: 400 mg lopinavir/100 mg ritonavir cada 12 horas.
![Page 17: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/17.jpg)
TRATAMIENTO
![Page 18: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/18.jpg)
COMPARACION TARGA TEMPRANA VS STANDARD
![Page 19: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/19.jpg)
COMPARACION TARGA TEMPRANA VS STANDARD
![Page 20: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/20.jpg)
ESQUEMAS TARGA
![Page 21: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/21.jpg)
![Page 22: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/22.jpg)
![Page 23: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/23.jpg)
![Page 24: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/24.jpg)
![Page 25: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/25.jpg)
![Page 26: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/26.jpg)
![Page 27: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/27.jpg)
![Page 28: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/28.jpg)
![Page 29: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/29.jpg)
PROFILAXIS PRE-EXPOSICIÓN EN HETEROSEXUALES
![Page 30: 3. ITS VIH SIDA](https://reader031.vdocuments.us/reader031/viewer/2022020208/563db80e550346aa9a902ae3/html5/thumbnails/30.jpg)
INICIO PRECOZ (2 SEM) VS INICIO TARDIO (8 SEM) TARGA EN TBC